<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00216216</url>
  </required_header>
  <id_info>
    <org_study_id>HOG LUN04-78</org_study_id>
    <nct_id>NCT00216216</nct_id>
  </id_info>
  <brief_title>Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer</brief_title>
  <official_title>Pemetrexed (Alimta) in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study (LUN04-78)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoosier Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walther Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with relapsed or chemotherapy-refractory SCLC have a dismal prognosis.
      Unfortunately, available treatments result in few durable responses. Pemetrexed is a
      well-tolerated agent, which is active in NSCLC. Since chemotherapy agents, which are active
      in NSCLC, are usually also active in SCLC, this trial will examine the efficacy and activity
      of pemetrexed in this palliative setting
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a multi-center study.

        -  Pemetrexed 500 mg/m2 i.v. q 3 wks

      All patients will also receive folic acid 350-1000 mcg. po once daily beginning approximately
      1 week prior to the first dose of pemetrexed and continuing until completion of pemetrexed,
      Vitamin B12 1000 mcg. IM every 9 weeks beginning approximately 1 week prior to the first dose
      of pemetrexed and continuing until completion of pemetrexed, and dexamethasone 4 mg po bid
      the day before, the day of, and the day following each treatment with pemetrexed

      Chest x-ray will be performed prior to each cycle (if other disease assessment by imaging is
      not performed) in order to ensure patients are not rapidly progressing.

      Cycles are repeated every 3 weeks for up to 6 cycles or PD or intolerable side effects.

      Performance Status: ECOG 0, 1, or 2

      Life Expectancy: Not specified

      Hematopoietic:

        -  WBC &gt; 3000/mm3

        -  ANC &gt; 1500/mm3

        -  Platelet count &gt; 100,000/mm3

        -  Hemoglobin &gt; 8 g/dL

      Hepatic:

        -  Bilirubin &lt; 1.0 X upper limit of normal

        -  Aspartate aminotransferase (AST, SGOT) &lt; 2.5 x upper limit of normal. AST may be &lt; 5 x
           upper limit of normal for patients with liver metastasis

      Renal:

        -  Creatinine clearance of &gt; 45 ml/ min (by Cockcroft-Gault)

      Cardiovascular:

        -  No unstable or uncompensated cardiovascular conditions

      Pulmonary:

        -  No unstable or uncompensated respiratory conditions
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The results from the interim analysis were not favorable to continue this trial.
  </why_stopped>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- To estimate the clinical benefit rate (CR, PR, SD) of pemetrexed in two patient populations with small cell lung cancer: chemosensitive and chemoresistant relapsed independently.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the toxicity of pemetrexed; To estimate the time to disease progression; To estimate overall survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pemetrexed for patients with chemosensitive and chemoresistant relapsed small cell lung cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed 500 mg/m2 IV q 3 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological proof of neuroendocrine cancers (including small cell
             cancers of any site [including lung] or poorly differentiated neuroendocrine cancers
             of the lung with (unidimensionally) measurable disease as per the RECIST criteria

          -  Chemoresistant or chemosensitive disease

          -  Patients must have received treatment with at least one but not more than 2 prior
             chemotherapy regimens, including one regimen containing a platinum agent

          -  Radiation therapy must have completed their radiation at least 14 days prior to being
             registered for protocol therapy, and toxicities due to radiation must have recovered
             to &lt; grade 1 or baseline prior to registration

          -  Negative pregnancy test

        Exclusion Criteria:

          -  No clinically significant infections as judged by the treating investigator

          -  No symptomatic CNS metastasis

          -  No radiation to &gt; 25% of the marrow containing spaces

          -  No previous treatment with pemetrexed

          -  No uncontrolled pleural effusions

          -  No current breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nasser Hanna, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hoosier Oncology Group, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helen F. Graham Cancer Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical &amp; Surgical Specialists, LLC</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkhart Clinic</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of SW Indiana</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Oncology &amp; Hematology, Inc</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Care at Goshen Health System</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46527</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Regional Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnett Cancer Care</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Consultants, P.C.</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Care, Inc., P.C.</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Cancer Research Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Oncology Associates</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP&amp;S Clinic</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://hoosieroncologygroup.org</url>
    <description>Hoosier Oncology Group Home Page</description>
  </link>
  <results_reference>
    <citation>Jalal S, Ansari R, Govindan R, Bhatia S, Bruetman D, Fisher W, Masters G, White A, Stover D, Yu M, Hanna N; Hoosier Oncology Group. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study. J Thorac Oncol. 2009 Jan;4(1):93-6. doi: 10.1097/JTO.0b013e31818de1e6.</citation>
    <PMID>19096313</PMID>
  </results_reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>April 28, 2011</last_update_submitted>
  <last_update_submitted_qc>April 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Nasser Hanna, M.D.</name_title>
    <organization>Hoosier Oncology Group</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

